Vaxcyte Ownership
| PCVX Stock | USD 91.70 3.16 3.57% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 117.3 M | Current Value 123.7 M | Avarage Shares Outstanding 65 M | Quarterly Volatility 30.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Vaxcyte |
Vaxcyte Stock Ownership Analysis
About 100.0% of the company shares are owned by institutional investors. The book value of Vaxcyte was at this time reported as 27.47. The company recorded a loss per share of 4.6. Vaxcyte had not issued any dividends in recent years. Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Vaxcyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. To find out more about Vaxcyte contact Grant MBA at 650 837 0111 or learn more at https://vaxcyte.com.Besides selling stocks to institutional investors, Vaxcyte also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Vaxcyte's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Vaxcyte's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Vaxcyte Quarterly Liabilities And Stockholders Equity |
|
Vaxcyte Insider Trades History
Less than 1% of Vaxcyte are currently held by insiders. Unlike Vaxcyte's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Vaxcyte's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Vaxcyte's insider trades
Vaxcyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaxcyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaxcyte backward and forwards among themselves. Vaxcyte's institutional investor refers to the entity that pools money to purchase Vaxcyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.7 M | Darwin Global Management, Ltd. | 2024-06-30 | 2.1 M | Perceptive Advisors Llc | 2024-09-30 | 2 M | Driehaus Capital Management Llc | 2024-06-30 | 1.9 M | Westfield Capital Management Company, Lp | 2024-09-30 | 1.7 M | Alliancebernstein L.p. | 2024-06-30 | 1.7 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.3 M | Fred Alger Management, Llc | 2024-09-30 | 1.2 M | Jennison Associates Llc | 2024-09-30 | 1.2 M | Fmr Inc | 2024-09-30 | 15.8 M | Vanguard Group Inc | 2024-09-30 | 11.4 M |
Vaxcyte Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaxcyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaxcyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaxcyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vaxcyte Outstanding Bonds
Vaxcyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaxcyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaxcyte bonds can be classified according to their maturity, which is the date when Vaxcyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Vaxcyte Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 5th of September 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.